The study sought to compare the risk of late outcome with a focus on very late definite stent thrombosis of the everolimus-eluting stent (EES) with that of the sirolimus-eluting stent (SES) at 3-year follow-up.
Values shown are mean AE SD, number (%), or n/N (%).
Denmark. An independent event committee, masked to treatment group assignment during the adju- Baseline patient characteristics are summarized in 17.4 AE 4.2 atm; p < 0.001) (12).
FIGURE 1 Time-to-Event Curves for Major Adverse Cardiac Events
Major adverse cardiac events are a composite of cardiac death, myocardial infarction, definite stent thrombosis, and target vessel revascularization. EES ¼ everolimus-eluting stent; MACE ¼ major adverse cardiac events; SES ¼ sirolimus-eluting stent.
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At 3 years, the composite endpoint MACE occurred in 142 patients (10.2%) in the EES group and in 163 patients (11.8%) in the SES group (HR: 0.86, 95% CI:
0.69 to 1.08) ( Fig. 1 and Table 2 2 and Table 2 ). Assessing TLR after censoring the patient at the time of the stent thrombosis (before TLR), the TLR rate did not differ significantly between the 2 groups: EES group, 3.5% vs. SES group.
3.3% (HR: 1.03, 95% CI: 0.69 to 1.55). Findings for the combined endpoint MACE were consistent across pre-specified stratified analyses (Fig. 3) . The main endpoints (cardiac death, MI, TVR) are presented separately for the first year and a separate landmark analysis from 1 to 3 years in Table 3 . Jensen et al. Like most stent trials, the SORT OUT IV trial was designed as a single-blind study, and we believe that the lack of double-blinding would not influence the results as all endpoints were objective and determined by an event committee who was blinded to treatment group assignment during the adjudication process. Therefore, we expect that the event rate in our study is representative of the real event rate among this patient population.
CONCLUSIONS

MACE rates did not differ significantly between EES-
and SES-treated patients at 3-year follow-up. A significant reduction of overall and very late definite stent thrombosis was found in the EES group.
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